top of page
iPharmaCenter

For sponsored articles, link insertions, and advertisements, please write to info@ipharmacenter.com


CDSCO Clears Durvalumab with FLOT as New Perioperative Standard for Gastric Cancer Patients in India | iPharmaCenter
CDSCO Clears Durvalumab AstraZeneca received regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) for the use of durvalumab in combination with FLOT chemotherapy, a regimen including fluorouracil, leucovorin, oxaliplatin, and docetaxel, as a perioperative treatment for adults with resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma. This marks the first and only immunotherapy-based perioperative regimen to demonstrate a survival a
Sun Pharma obtains DCGI nod to produce generic semaglutide injection for weight management in India | iPharmaCenter
Sun Pharmaceutical Industries has secured approval from the Drugs Controller General of India (DCGI) to manufacture and commercialize a generic variant of semaglutide injection in the domestic market. The therapy, belonging to the glucagon-like peptide-1 (GLP-1) receptor agonist class, is intended for long-term weight management in adults when combined with a healthy diet and regular physical activity. The company will introduce its generic semaglutide injection under the b
Sun Pharma Launches ILUMYA in India for Psoriasis Patients | iPharmaCenter
Sun Pharma Launches ILUMYA in India Sun Pharma has unveiled its globally recognized innovative medication, ILUMYA (Tildrakizumab), now available in India for managing moderate-to-severe plaque psoriasis. This advanced biologic therapy has garnered extensive acceptance among dermatologists in the United States and internationally as a reliable and safe option for treating this condition. Also read: Top pharmaceutical companies by revenues in 2025 Long-Term Efficacy of ILUMYA
AstraZeneca Secures CDSCO Approval for Durvalumab in Limited-Stage Small Cell Lung Cancer Treatment | iPharmaCenter
AstraZeneca has received approval from the Central Drugs Standard Control Organisation (CDSCO) for the import, sale, and distribution of...
Dr. Reddy’s Launches Toripalimab in India for Nasopharyngeal Carcinoma Treatment | iPharmaCenter
Dr. Reddy’s Laboratories has introduced Toripalimab in India, marking it as the first and only immuno-oncology therapy approved for...


Sanofi Secures Approval for Beyfortus in India to Shield Infants and Children from RSV | iPharmaCenter
Sanofi India announced the receipt of marketing authorization for Beyfortus (nirsevimab) from the Central Drugs Standard Control...


Indian Pharma News | 2024 | iPharmaCenter
May 21, 2024 Glenmark and BeiGene Collaborate to Market and Distribute Tislelizumab and Zanubrutinib in India Key Points: Tislelizumab:...


India Drug Approvals | 2024 | CDSCO | News | Updates | Media | iPharmaCenter
19th January, 2024 Tirzepatide Recommended alongside dietary adjustments and physical activity to enhance blood sugar management in...


India | Drug Approvals | Pharma News | 2024 | iPharmaCenter
January 03, 2024 AstraZeneca India Unveils Trastuzumab Deruxtecan for HER2-Positive Metastatic Cases AstraZeneca India has officially...


India new drug approvals | India Pharma | 2023 | CDSCO | Ministry of health news | iPharmaCenter
September 30, 2023 AstraZeneca received approval from CDSCO for palivizumab to prevent RSV infection. AstraZeneca approved palivizumab, a...


India | Healthcare News | Abbott to upgrade 75 PHCs | iPharmaCenter
September 26, 2023 Cipla initiated drone services to deliver medicines to difficult-to-reach terrains. Cipla Limited has unveiled an...


Department of Pharmaceuticals report emphasize on need of academia to meet industry's requirement
A study was conducted by the Department of Pharmaceuticals in India to assess the skills required for the Indian pharmaceutical industry....
bottom of page